FDA expands Xtandi's prostate cancer use

The FDA on 10 September gave Medivation and Astellas the go-ahead to market Xtandi (enzalutamide/MDV3100) as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) not previously treated with chemotherapy – expanding the drug's use.